BioAtla Revenue and Competitors

Location

$261.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • BioAtla's estimated annual revenue is currently $10.2M per year.(i)
  • BioAtla's estimated revenue per employee is $150,441
  • BioAtla's total funding is $261.5M.

Employee Data

  • BioAtla has 68 Employees.(i)
  • BioAtla grew their employee count by 13% last year.

BioAtla's People

NameTitleEmail/Phone
1
Chief Medical OfficerReveal Email/Phone
2
Chief Development & OperationsReveal Email/Phone
3
Chief Intellectual Property & Strategy, CofounderReveal Email/Phone
4
VP Technology DevelopmentReveal Email/Phone
5
Head RA/QAReveal Email/Phone
6
Head Regulatory AffairsReveal Email/Phone
7
VP Research/Development AsiaReveal Email/Phone
8
VP CMCReveal Email/Phone
9
VP Intellectual Property & ContractsReveal Email/Phone
10
VP, Human ResourcesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is BioAtla?

BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our Conditionally Active Biologics (CAB) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. This improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. BioAtla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.

keywords:N/A

$261.5M

Total Funding

68

Number of Employees

$10.2M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BioAtla News

2022-04-19 - BioAtla (BCAB) Set to Announce Quarterly Earnings on ...

Analysts expect BioAtla to post earnings of ($0.69) per share for the quarter. Investors interested in registering for the company's conference...

2022-04-17 - Comparing Mesoblast (NASDAQ:MESO) & BioAtla (NASDAQ ...

Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Mesoblast.

2022-03-30 - BioAtla to Announce First Quarter 2022 Financial Results and ...

About BioAtla, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China...

2021-11-16 - BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the third quarter of 2021 and provided an update on ...

2021-09-29 - BioAtla : Announces Private Placement of 2.7 Million Shares

SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of instit ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.2M6810%N/A
#2
$11M68N/AN/A
#3
$14M686%N/A
#4
$13.5M688%N/A
#5
$16.5M688%N/A